NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Stem cell superlatives without caveats

Posted By

Tags

ABC World News Tonight broadcast a story last night, a portion of which is captured on their website, about patients’ own stem cells used to build new blood vessels.

It is interesting clinical research, but the story offered only breathlessly optimistic projections — no caveats, warnings, unknowns or uncertainties. An excerpt: “Results in more than 100 patients show that, within just three months after the stem cell injections, patients see a significant improvement in blood flow to the heart. The heart muscle itself actually doubles its ability to squeeze or contract.

The short-term results (3 months) send up one red flag. Another is the use of what are called surrogate endpoints. In other words, rather than reporting that people lived longer (which of course would be a pretty empty projection after only 3 months), they reported a different marker or endpoint to measure “success.” That is, blood flow to the heart.

But the coup de grâce comes with the next line of the story: “Researchers say these adult stem cells might help tens of millions of heart patients each year.”

Or, the story could be just as true to the facts and conclude, “Maybe not.” The science behind this work holds great potential. It doesn’t need hyping of short-term research measuring only surrogate endpoints that extrapolates these early findings to tens of millions of people.

You might also like

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.